iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
To compare recurrent ovarian cancer trials, first check whether they studied similar patients and treatments; then compare study design, endpoint definitions, follow-up, uncertainty, side effects, and patient-reported outcomes. A higher response rate or longer progression-free survival in one study does not, by itself, prove that its treatment is better for a particular person.
Start with the patients and treatment context
Two studies are not directly comparable simply because both concern recurrent ovarian cancer. Look for the disease subtype, eligibility criteria, prior treatments, and how the trial describes the cancer’s relationship to platinum-based therapy. Trials may also include fallopian tube or primary peritoneal cancers. The National Cancer Institute’s treatment overview describes approaches for recurrent or persistent ovarian, fallopian tube, and primary peritoneal cancers; it does not mean every approach applies to every patient or subtype.
- Population: Which cancer types and histologies were eligible? Were participants at a similar point in their disease course?
- Prior treatment: What therapies had participants received, and were there limits on the number or type of previous regimens?
- Platinum context: How did the study characterize platinum sensitivity or resistance? Check the trial’s own definitions rather than assuming the labels mean the same thing across studies.
- Eligibility: Consider any other requirements that could make participants healthier, more treatment-tolerant, or otherwise different from the person you have in mind.
NCI records illustrate why these details matter: the EFFORT trial and the KEYNOTE-B96 / ENGOT-ov65 trial describe their own populations and regimens. Their shared connection to ovarian cancer is not enough to make their results an apples-to-apples comparison.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Check the design before interpreting a result
Find out whether a study was randomized and what comparator it used. A randomized study can compare assigned treatment strategies within the trial; an uncontrolled, single-arm study reports what happened to participants receiving the study treatment but has no concurrent comparison group. Also note the phase, number enrolled and analyzed, follow-up, and whether the reported results are interim or final.
#1 Best Overall
- Randomized trial: Identify the control or comparison arm and the analysis used to compare groups. Check whether the result is a relative comparison, an absolute difference, or both.
- Uncontrolled trial: Treat response or disease-control findings as observations in that selected group, not as proof that the treatment outperforms another option.
- Sample and follow-up: Smaller samples and shorter observation can leave more uncertainty, especially for outcomes that take time to occur.
The authors of the 2009 RECIST 1.1 guideline caution that in an uncontrolled trial, an apparently promising observation “may be related to biological factors such as patient selection and not the impact of the intervention.” This is a warning about interpreting study design, not a judgment about any particular ovarian cancer treatment. Read the RECIST 1.1 guideline.
Know what each endpoint measures
Endpoint names answer different questions. Read each trial’s definition, starting point, assessment schedule, criteria, assessor, and analysis population before comparing its numbers. NCI trial records, for example, define outcomes within their own protocols; a label alone does not guarantee identical measurement.
| Endpoint | What it measures | What to check |
|---|---|---|
| Objective response rate (ORR) | The proportion of participants whose tumors meet the study’s definition of complete or partial response. | Response criteria, assessor, assessment timing, and which participants were included in the denominator. ORR describes how many responded, not how long responses lasted. |
| Progression-free survival (PFS) | Time from a study-defined starting point until documented progression or death, according to the protocol. | Starting point, progression rules, scan schedule, censoring, follow-up, and analysis population. One NCI record, for example, defines PFS from the first cycle to documented progression or death; other studies may use different definitions. See the avelumab and stereotactic body radiation trial record. |
| Overall survival (OS) | Time from the study-defined starting point until death. | Starting point, follow-up, and analysis. OS is distinct from tumor shrinkage and PFS; NCI recurrent-disease protocols list it separately from those outcomes. |
| Duration of response | How long a response lasts among participants who responded, measured from the first documented response to progression under the applicable criteria. | Response definition, start and end rules, and follow-up. Because it concerns responders, it answers a different question from ORR. |
Compare how tumors and time-to-event outcomes were assessed
RECIST 1.1 is used in NCI-listed ovarian cancer trials, but individual protocols still specify how assessments were conducted, including whether investigators assessed response. Compare the criteria and who made the assessment rather than assuming that the same endpoint label means the same procedure.
For time-to-event outcomes, scan timing affects when progression can be detected. The RECIST 1.1 guideline says that when a time-to-event measure such as PFS is the main endpoint, “routine scheduled re-evaluation of protocol specified sites of disease is warranted.” That makes the trial’s imaging schedule and follow-up rules important context for reading PFS results.
For example, the NCI’s APL-2 and pembrolizumab trial record and KEYNOTE-B96 / ENGOT-ov65 trial record describe trial-specific outcomes and assessment details. Use the record or publication for the exact criteria, assessor, schedule, and analysis population; do not infer those details from an endpoint’s abbreviation.
Look at effect size and uncertainty together
A reported estimate is not the whole result. In a randomized comparison, examine the difference between arms and its uncertainty, not just whether a result is described as favorable or statistically significant. In any study, check how many participants contributed to the analysis, how much follow-up was available, and whether the estimate is precise enough to support a useful conclusion.
Do not compare a planned endpoint with a reported outcome: trial objectives tell you what investigators intend to measure, not what they found. The cited records and guideline provide examples of trial designs and endpoints, but they do not establish a verified set of final outcome estimates for ranking recurrent ovarian cancer treatments.
Free tools Windows power users keep installed
One-click scans. No signup required.
Include harms and the experience of treatment
Efficacy endpoints do not describe the full trade-off. Compare adverse-event definitions and severity, how long participants were exposed to treatment, and how often treatment was stopped because of side effects. Check whether safety results cover all treated participants and use comparable reporting periods.
Best Value
Also look for symptoms and quality of life measured directly from participants. Instruments used in trial examples include EORTC questionnaires such as QLQ-C30 or OV28 and NFOSI-18. Compare the instrument, when it was administered, how many participants completed it, and what was reported; a questionnaire’s inclusion alone does not show that daily life improved.
NCI trial records such as EFFORT identify safety outcomes, while the NRG-GY004 protocol includes patient-reported outcome measures. These are examples of what to look for, not evidence that the trials had the same results or burden.
Use a practical comparison checklist
- Open the full trial record or publication. Note the cancer type, eligibility criteria, prior therapy, and platinum context.
- Record the design. Write down phase, randomization, comparator, sample, follow-up, and whether the report is interim or final.
- Copy each endpoint definition. For ORR, PFS, OS, and duration of response, capture the starting point, response criteria, assessor, assessment schedule, and analysis population.
- Read the results with their uncertainty. Distinguish observed outcomes from planned objectives and examine estimates alongside sample size and follow-up.
- Compare burden as well as benefit. Review serious and other adverse events, treatment discontinuations, and patient-reported symptoms or quality of life.
- Relate the evidence to the individual case. Ask the treating oncology team which differences in eligibility, previous treatment, and outcome measurement matter most.
Find current trial information
The NCI’s ovarian cancer clinical trials search can help locate records and filter by location and other criteria. Recruitment status, eligibility, and locations can change, so check the current record and confirm details with the study team. A trial’s listing does not establish that it is appropriate for a specific patient.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
